INDIANAPOLIS (Dec. 4, 2020) Elanco Animal Health Inc. (NYSE: ELAN), which is now the second-largest independent animal health company in the world, announced plans today to locate its global headquarters in Indiana following its 2018 IPO and recent acquisition of Bayer Animal Health. The company will invest in its Indiana operations to position Elanco for future growth as an independent company, making Indiana its base of operations and locating its global headquarters on 45 acres of a 91-acre former industrial site on the southwest corner of downtown Indianapolis that has sat vacant since the General Motors (GM) stamping plant closure in 2011.
It is a momentous day for the state of Indiana as we celebrate Elancos decision to establish its global headquarters in central Indiana, positioning itself for future growth and consolidation in the Hoosier state and creating hundreds of high-paying jobs for Hoosiers, said Governor Eric J. Holcomb. Elanco is an important asset to Indiana – a leader in our growing agbioscience sector, which is poised to grow and continue innovating. We are thrilled with the direction of Elancos future and the transformational impact its growth will have on the agbioscience sector, the downtown Indianapolis footprint, and most importantly, the lives of Hoosier workers.
Elanco plans new global headquarters campus, base of operations in Indiana
After a multi-state search process, Elanco, which develops products and knowledge services to prevent and treat disease in farm animals and pets in 90 countries, will locate its global headquarters in Indianapolis, constructing and equipping a future-focused global headquarters campus on 45 acres of the former GM stamping plant industrial site on the citys near westside. The new site will allow Elanco to consolidate its global operations and more than 1,000 team members at one location and enable the company to design a smarter, more modern, fit-for-purpose campus with collaborative, flexible spaces that support the future of work.
Anchored by this new headquarters, the company will invest more than $300 million in its Indiana operations, establishing its base of operations and a center of excellence in Indiana and ensuring the Hoosier state is at the center of its future growth and future consolidation. Elanco will retain its manufacturing centers in Clinton, Indianapolis and Terre Haute and plans to center its R&D activity in the state to support its continued growth and innovation.
With a shared vision for the future of the agbioscience industry in Indiana, we are pleased Elanco can serve as a catalyst through our global headquarters and base of future operations in Indianapolis, said Elanco president and CEO Jeff Simmons. In partnership with Governor Holcomb, Mayor Hogsett and IEDC, we look forward to continuing our nearly 70-year history here and serving our new community. Indiana has created a strong environment for business, and we have deep appreciation for local leaders that have worked to position the Hoosier state for the future.
A dedicated Elanco build team will begin planning for the downtown site immediately, and the company expects to break ground in Indianapolis in the first half of 2021. Elanco, which is currently headquartered 25 miles east in Greenfield, expects the new headquarters to be complete in the next two to three years. The company is committed to working aggressively in partnership with the state to identify leasing options for its current facility to ensure a smooth transition and ongoing quality career opportunities in Greenfield.
Decision will retain 1,600+, create 570+ new, highly skilled, high-wage jobs
Elanco currently operates 19 manufacturing facilities and employs approximately 9,000 associates worldwide. With its decision to anchor its corporate headquarters and base of operations in Indiana, Elanco is committed to retaining the more than 1,600 Hoosiers it employs across its corporate and manufacturing operations throughout the state over the next decade and to helping relocate more roles to Indiana, with the support of the Indiana Economic Development Corporation (IEDC). The company will create up to approximately 575 new, high-wage jobs in Indiana by the end of 2030 to support its global headquarters and innovation operations.
Elancos Indiana workforce will enable the newly independent company, which finalized its separation from Eli Lilly and Company in 2019, to grow as a stand-alone company. Its recent $6.8 billion acquisition of Germany-based Bayer Animal Health makes Elanco the second-largest independent animal health company in the world. Anyone interested in a career at Elanco may view open positions and apply at www.elanco.com/careers.
STATEHOUSE (Dec. 4, 2020) “Indiana continues to flex its economic muscle as a destination to do business, and Elanco’s decision to establish its new global headquarters and base of operations here builds our momentum for growth and prosperity,” said Indiana Lt. Gov. Suzanne Crouch, who serves as Secretary of Agriculture and Rural Development. “The animal agriculture sector has contributed greatly to our state’s long and rich agriculture heritage, and this announcement will boost Indiana’s place in the country to attract talent in the agbiosciences.”